The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is the examine the effect of taking exenatide on the blood levels (pharmacokinetics) of orally-administered contraceptives.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Eli Lilly and Company
• Treatments: Contraceptive Agents; Contraceptives, Oral; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Exenatide; Levonorgestrel; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Pre-menopausal female of child-bearing potential.

• Body Mass Index (BMI) between 19 and 35 kg/m^2, inclusive.

Exclusion Criteria:

• On implanted contraceptives for 6 months, or injectable contraceptives for 12 months prior to the study.

• Evidence of diabetes mellitus.

• Participation in a study involving administration of an investigational compound within the past 3 months.